Skip to main content

ACS & ASCO are Stronger Together: Cancer.Net content is now available on

Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors

For most types of cancer, determining the stage (extent) of the cancer is very important. The stage is based on the size of the main tumor and how far the cancer has spread. This can be helpful in predicting a person’s outlook and deciding on treatment.

Acute myeloid leukemia (AML), on the other hand, does not usually form tumors. It generally is widespread throughout the bone marrow and, in some cases, has spread to other organs, such as the liver and spleen. Therefore AML is not staged like most other cancers. The outlook for a person with AML depends instead on other information, such as the subtype of AML (determined by lab tests), the patient’s age, and other lab test results.

Knowing the subtype of AML can be very important, as it sometimes affects both a patient’s outlook and the best treatment. For example, the acute promyelocytic leukemia (APL) subtype is often treated using drugs that are different from those used for other subtypes of AML. If you're not sure which subtype of AML you have, ask your doctor about it, and about how it might affect your treatment.

Two of the main systems that have been used to classify AML into subtypes are the French-American-British (FAB) classification and the newer World Health Organization (WHO) classification.

The French-American-British (FAB) classification of AML

In the 1970s, a group of French, American, and British leukemia experts divided AML into subtypes, M0 through M7, based on the type of cell the leukemia develops from and how mature the cells are. This was based largely on how the leukemia cells looked under the microscope after routine staining.

FAB subtype



Undifferentiated acute myeloblastic leukemia


Acute myeloblastic leukemia with minimal maturation


Acute myeloblastic leukemia with maturation


Acute promyelocytic leukemia (APL)


Acute myelomonocytic leukemia

M4 eos

Acute myelomonocytic leukemia with eosinophilia


Acute monocytic leukemia


Acute erythroid leukemia


Acute megakaryoblastic leukemia

Subtypes M0 through M5 all start in immature forms of white blood cells. M6 AML starts in very immature forms of red blood cells, while M7 AML starts in immature forms of cells that make platelets.

World Health Organization (WHO) classification of AML

The FAB classification system can be useful, but it doesn’t take into account many of the factors that are now known to affect prognosis (outlook). The World Health Organization (WHO) system, most recently updated in 2016, includes some of these factors to try to better classify AML.

The WHO system divides AML into several groups:

AML with certain genetic abnormalities (gene or chromosome changes)

  • AML with a translocation between chromosomes 8 and 21 [t(8;21)]
  • AML with a translocation or inversion in chromosome 16 [t(16;16) or inv(16)]
  • APL with the PML-RARA fusion gene
  • AML with a translocation between chromosomes 9 and 11 [t(9;11)]
  • AML with a translocation between chromosomes 6 and 9 [t(6:9)]
  • AML with a translocation or inversion in chromosome 3 [t(3;3) or inv(3)]
  • AML (megakaryoblastic) with a translocation between chromosomes 1 and 22 [t(1:22)]
  • AML with the BCR-ABL1 (BCR-ABL) fusion gene*
  • AML with mutated NPM1 gene
  • AML with biallelic mutations of the CEBPA gene (that is, mutations in both copies of the gene)
  • AML with mutated RUNX1 gene*

*This is still a "provisional entity," meaning it's not yet clear if there's enough evidence that it's a unique group.

AML with myelodysplasia-related changes

AML related to previous chemotherapy or radiation

AML not otherwise specified (This includes cases of AML that don’t fall into one of the above groups, and is similar to the FAB classification.)

  • AML with minimal differentiation (FAB M0)
  • AML without maturation (FAB M1)
  • AML with maturation (FAB M2)
  • Acute myelomonocytic leukemia (FAB M4)
  • Acute monoblastic/monocytic leukemia (FAB M5)
  • Pure erythroid leukemia (FAB M6)
  • Acute megakaryoblastic leukemia (FAB M7)
  • Acute basophilic leukemia
  • Acute panmyelosis with fibrosis

Myeloid sarcoma (also known as granulocytic sarcoma or chloroma)

Myeloid proliferations related to Down syndrome

Undifferentiated and biphenotypic acute leukemias are not strictly AML, but are leukemias that have both lymphocytic and myeloid features. They are sometimes called mixed phenotype acute leukemias (MPALs).

Prognostic factors for AML

The subtype of AML can be important in helping to determine a person's prognosis (outlook). But other factors can also affect why some patients with AML have a better outlook than others. These are called prognostic factors. Prognostic factors help doctors determine a person's risk of the leukemia coming back after treatment, and therefore if they should get more or less intensive treatment. Some of these include:

Chromosome (cytogenetic) abnormalities

AML cells can have many kinds of chromosome changes, some of which can affect a person’s prognosis. Those listed below are some of the most common, but there are many others. Not all leukemias have these abnormalities. Patients whose AML doesn't have any of these usually have an outlook that is between favorable and unfavorable.

Favorable abnormalities:

  • Translocation between chromosomes 8 and 21 (seen most often in patients with M2)
  • Translocation or inversion of chromosome 16
  • Translocation between chromosomes 15 and 17 (seen most often in patients with M3)

Unfavorable abnormalities:

  • Deletion (loss) of part of chromosome 5 or 7
  • Translocation or inversion of chromosome 3
  • Translocation between chromosomes 6 and 9
  • Translocation between chromosomes 9 and 22
  • Abnormalities of chromosome 11 (at the spot q23)
  • Loss of a chromosome, so the cell has only 1 copy instead of the normal 2 (known as monosomy)
  • Complex changes (those involving 3 or more chromosomes)

Gene mutations

People whose leukemia cells have certain gene mutations may have a better or worse outlook.

For instance, people with AML that has a mutation in the FLT3 gene tend to have a poorer outlook, although new drugs that target cells with this abnormal gene might lead to better outcomes. Mutations in the TP53, RUNX1, and ASXL1 genes are also linked with a worse outlook.

On the other hand, people whose leukemia cells have changes in the NPM1 gene (and no other abnormalities) seem to have a better prognosis than people without this change. Changes in both copies of the CEBPA gene are also linked to a better outcome.

Markers on the leukemia cells

If the leukemia cells have the CD34 protein and/or the P-glycoprotein (MDR1 gene product) on their surface, it is linked to a worse outlook.


Generally, people over 60 don’t do as well as younger people. Some of this may be because they are more likely to have unfavorable chromosome abnormalities. They sometimes also have other medical conditions that can make it harder for them to handle more intense chemotherapy regimens.

White blood cell count

A high white blood cell count (>100,000/mm3) at the time of diagnosis is linked to a worse outlook.

Prior blood disorder leading to AML

Having a prior blood disorder such as a myelodysplastic syndrome is linked to a worse outlook.

Treatment-related AML

AML that develops after a person is treated for another cancer is linked to a worse outlook.


Having a systemic (blood) infection when you are diagnosed is linked to a worse outlook.

Leukemia cells in the central nervous system

Leukemia that has spread to the area around the brain and spinal cord can be hard to treat, since most chemotherapy drugs can’t reach that area.

Status of AML after treatment

How well (and how quickly) the leukemia responds to treatment also affects long-term prognosis. Better initial responses have been linked with better long-term outcomes.

A remission (complete remission) is usually defined as having no evidence of disease (NED) after treatment. This means the bone marrow contains fewer than 5% blast cells, the blood cell counts are within normal limits, and there are no signs or symptoms from the leukemia. A complete molecular remission means there is no evidence of leukemia cells in the bone marrow, even when using very sensitive tests, such as PCR (polymerase chain reaction).

Minimal residual disease (MRD) is a term used after treatment when leukemia cells can’t be found in the bone marrow using standard tests (such as looking at cells under a microscope), but more sensitive tests (such as flow cytometry or PCR) find evidence that there are still leukemia cells in the bone marrow.

Active disease means that either there is evidence that the leukemia is still present during treatment, or that the disease has come back after treatment (relapsed). For a patient to have relapsed, they must have more than 5% blast cells in their bone marrow.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

National Cancer Institute. Physician Data Query (PDQ). Adult Acute Myeloid Leukemia Treatment. 2018. Accessed at on June 17, 2018.National Comprehensive Cancer Network.

NCCN Practice Guidelines in Oncology: Acute Myeloid Leukemia. V.1.2018. Accessed at on June 17, 2018.

Schiffer CA, Gurbuxani S. Classification of acute myeloid leukemia. UpToDate. 2018. Accessed at on June 17, 2018.

Last Revised: August 21, 2018

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.